Syncona Ltd.

04/02/2024 | Press release | Distributed by Public on 04/02/2024 07:00

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.